Biotin (B7)

Overview

Biotin, designated vitamin B7 (also historically vitamin H or coenzyme R), is a water-soluble vitamin. It is not a peptide. The molecule is included here as a cofactor entry because it is sold by research compound vendors alongside peptides and has acquired a substantial consumer-research profile that warrants a calibrated reference page.

The biological function of biotin is unambiguous and well characterized. It serves as the covalently attached cofactor for the five mammalian carboxylase enzymes: pyruvate carboxylase (gluconeogenesis), acetyl-CoA carboxylase 1 and 2 (fatty acid synthesis and oxidation regulation), propionyl-CoA carboxylase (odd-chain fatty acid and branched-chain amino acid metabolism), 3-methylcrotonyl-CoA carboxylase (leucine catabolism), and the urea cycle’s involvement is indirect. Each carboxylase requires biotin to perform an ATP-dependent CO2-fixation step central to its substrate’s metabolism.

Dietary biotin requirements are minimal, on the order of 30 micrograms per day for adults, and frank deficiency is rare in well-nourished populations. Endogenous biotin recycling through the enzyme biotinidase liberates biotin from spent carboxylases and from dietary biotin-protein conjugates, sustaining normal carboxylase function. The clinically recognized syndrome of biotinidase deficiency, a genetic disorder, responds dramatically to high-dose biotin supplementation and is the indication for which biotin is most firmly evidence-supported as a therapeutic.

Mechanism of Action

Carboxylase Cofactor

Biotin attaches covalently to a specific lysine residue on each carboxylase enzyme through the action of holocarboxylase synthetase, forming a biotinyl-enzyme intermediate. The biotin moiety swings between two active sites on the enzyme, picking up a carboxyl group from bicarbonate and depositing it onto the substrate. This bicycle-pedal mechanism is conserved across all biotin-dependent carboxylation reactions.

Biotin Recycling

Biotinidase liberates biotin from biocytin (biotin-lysine) and from biotinyl-peptides generated during carboxylase turnover, returning the cofactor to the recycling pool. Genetic loss of biotinidase function produces a phenotype of organic aciduria, neurologic abnormalities, and skin and hair findings that responds to high-dose oral biotin.

Histone Biotinylation (Preliminary)

A subset of preclinical work has reported biotin attachment to histone proteins as a candidate epigenetic modification. The functional significance and even the in vivo abundance of histone biotinylation remain debated in the chromatin biology literature.

Research Summary

Biotinidase Deficiency

Wolf (2010 review, Genetics in Medicine) summarized the clinical management of biotinidase deficiency, the genetic condition for which biotin supplementation is established as essential and effective. This is the strongest indication for biotin as a therapeutic.

Hair Loss and Cosmetic Indications

Patel, Swink, and Castelo-Soccio (2017, Skin Appendage Disorders) reviewed the published evidence for biotin in hair loss outside of biotinidase deficiency. The authors concluded that supporting evidence is largely limited to case reports in patients with underlying biotin deficiency or biotinidase impairment, with limited high-quality evidence supporting routine use in non-deficient adults. Despite this, biotin remains widely marketed for hair, skin, and nail support, with consumer products often containing several thousand micrograms per dose, far above dietary requirements.

Multiple Sclerosis

High-dose biotin (300 mg per day, designated MD1003) was investigated in progressive multiple sclerosis through a Phase IIb trial reported by Tourbah et al. (2016, Multiple Sclerosis Journal). The Phase III SPI2 trial (Cree et al., 2020) failed to demonstrate efficacy, and the MD1003 program was subsequently discontinued.

Diabetic Neuropathy

Several smaller trials in the 1990s and 2000s investigated biotin in diabetic neuropathy with mixed results. The methodological quality of the available studies has limited definitive conclusions.

Research Status and Laboratory Assay Interference

A clinically important and frequently underappreciated consequence of high-dose biotin supplementation is interference with biotin-streptavidin-based laboratory assays. The FDA issued a safety communication in 2017 highlighting cases of false-low troponin results in patients taking high-dose biotin, which had led to missed myocardial infarction diagnoses. This effect is reviewed in Holmes and Babwah (2017, JAMA) and other clinical chemistry publications. Patients undergoing cardiac biomarker, thyroid hormone, or hormone immunoassay testing should disclose biotin use, and providers should account for the assay interference window.

Dosing in Published Research

Biotin (vitamin B7) is an essential nutrient rather than a research drug, so it does not have a clinical “dose” in the usual sense. Because human requirements are low and frank deficiency is rare, no Recommended Dietary Allowance has been set. Instead, the National Academies have established an Adequate Intake of 30 micrograms per day for adults (35 micrograms per day during breastfeeding). Many marketed supplements contain far higher amounts, but no established benefit has been demonstrated for high-dose biotin in people who are not deficient. These figures are drawn from the National Academies dietary reference intakes, as summarized by the NIH Office of Dietary Supplements.

Frequently Asked Questions